Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation

Brian T. O’Neill(Pfizer (United States)), Michael A. Brodney(Vertex Pharmaceuticals (United States)), Gabriela Barreiro(Pfizer (United States)), Cathleen Gonzales, Claire M. Steppan(University of Pittsburgh), David Riddell(Eli Lilly (United States)), Kimberly Lapham(Scripps Research Institute), Erik LaChapelle(Pfizer (United States)), Luis Martinez-Alsina(Pfizer (United States)), Christopher Houle(Pfizer (United States)), Katherine Hales(Pfizer (United States)), Germaine Boucher(Pfizer (United States)), Leanne M. Buzon(Pfizer (United States)), Kevin Ogilvie(Pfizer (United States)), Xinjun Hou(Pfizer (United States)), Lorraine F. Lanyon(Scripps Research Institute), David A. Karanian(Pfizer (United States)), Charles E. Nolan(Pfizer (United States)), Shawn D. Doran(Pfizer (United States)), Claude Ambroise(Pfizer (United States)), John C. Murray(Pfizer (United States)), Ashley Robshaw(Pfizer (United States)), Cheng Chang(Pfizer (United States)), Lei Zhang(Pfizer (United States)), Christopher R. Butler(Pfizer (United States)), Karamjeet Pandher(Pfizer (United States)), Elizabeth M. Beck(Pfizer (United States)), Anabella Villalobos(Pfizer (United States)), Kelly R. Bales(Eli Lilly (United States)), Bruce N. Rogers(Pfizer (United States)), Jason K. Dutra(Pfizer (United States))

Journal of Medicinal Chemistry

April 3, 2018

Cited by 42

|Neuron|2008|869

|Nature Neuroscience|2002|858

|Nature Genetics|1997|835

|Proceedings of the National Academy of Sciences|2005|659

|Journal of Medicinal Chemistry|2012|460

Related Papers